Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload.

Duca L, Cappellini MD, Baronciani D, Pilo F, Targhetta C, Visani G, Nava I, Angelucci E.

Am J Hematol. 2018 Jul 7. doi: 10.1002/ajh.25201. [Epub ahead of print] No abstract available.

PMID:
29981284
2.

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach.

Isidori A, Loscocco F, Ciciarello M, Corradi G, Lecciso M, Ocadlikova D, Parisi S, Salvestrini V, Amadori S, Visani G, Curti A.

Cancers (Basel). 2018 Jun 22;10(7). pii: E211. doi: 10.3390/cancers10070211. Review.

3.

Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome.

Visani G, Loscocco F, Isidori A, Piccaluga PP.

Expert Rev Hematol. 2018 Jun;11(6):455-461. doi: 10.1080/17474086.2018.1475225. Epub 2018 May 24.

PMID:
29792762
4.

Iron toxicity - Its effect on the bone marrow.

Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P.

Blood Rev. 2018 Apr 13. pii: S0268-960X(17)30150-9. doi: 10.1016/j.blre.2018.04.004. [Epub ahead of print] Review.

PMID:
29699840
5.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

PMID:
29499087
6.

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.

Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R.

Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2.

PMID:
29396857
7.

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.

Visani G, Loscocco F, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A.

Pharmacogenomics J. 2018 May 22;18(3):444-449. doi: 10.1038/tpj.2017.48. Epub 2017 Dec 5.

PMID:
29205204
8.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

9.

Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.

Visani G, Ferrara F, Di Raimondo F, Loscocco F, Fuligni F, Paolini S, Zammit V, Spina E, Rocchi M, Visani A, Piccaluga PP, Isidori A.

Leuk Res. 2017 Nov;62:77-83. doi: 10.1016/j.leukres.2017.09.019. Epub 2017 Sep 25.

10.

Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.

Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S.

Cancer Res. 2017 Jul 1;77(13):3685-3699. doi: 10.1158/0008-5472.CAN-17-1098. Epub 2017 May 23.

11.

Secondary bone marrow malignancies after adjuvant chemotherapy for breast cancer: a report of 2 cases and a review of the literature.

Rossi D, Sarti D, Malerba L, Tommasoni S, Visani G, Martignetti A, Fiorentini G.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000489.

PMID:
26979247
12.

Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia.

Visani G, Manti A, Valentini L, Canonico B, Loscocco F, Isidori A, Gabucci E, Gobbi P, Montanari S, Rocchi M, Papa S, Gatti AM.

Leuk Res. 2016 Nov;50:50-56. doi: 10.1016/j.leukres.2016.09.004. Epub 2016 Sep 3.

PMID:
27669365
13.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Haematologica. 2016 Oct;101(10):1200-1207. Epub 2016 Jul 28.

14.

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.

Isidori A, Christofides A, Visani G.

Leuk Lymphoma. 2016 Nov;57(11):2499-509. doi: 10.1080/10428194.2016.1185785. Epub 2016 May 31. Review.

PMID:
27243412
15.

AML therapy in the elderly: a time for a change.

Isidori A, Loscocco F, Visani G.

Expert Opin Drug Saf. 2016 Jul;15(7):891-2. doi: 10.1080/14740338.2016.1176139. Epub 2016 Apr 18. No abstract available.

PMID:
27054576
16.

Enteric-coated mycophenolate sodium: a new option for GHVD prophylaxis?

Isidori A, Loscocco F, Malerba L, Clissa C, Guiducci B, Visani G.

Eur J Haematol. 2017 Apr;98(4):320-321. doi: 10.1111/ejh.12739. No abstract available.

PMID:
26800509
17.

PBSC mobilization in patients with autoimmune diseases: what's next.

Isidori A, Loscocco F, Guiducci B, Malerba L, Clissa C, Visani G.

Eur J Haematol. 2016 Jul;97(1):5-6. doi: 10.1111/ejh.12701. No abstract available.

PMID:
26567799
18.

Advancement in high dose therapy and autologous stem cell rescue in lymphoma.

Isidori A, Clissa C, Loscocco F, Guiducci B, Barulli S, Malerba L, Gabucci E, Visani G.

World J Stem Cells. 2015 Aug 26;7(7):1039-46. doi: 10.4252/wjsc.v7.i7.1039. Review.

19.

Nanocarriers targeting cancer stem cells: how to help drugs to find their way home.

Visani G, Loscocco F, Isidori A.

Nanomedicine (Lond). 2015;10(7):1043-6. doi: 10.2217/nnm.15.8. No abstract available.

PMID:
25929562
20.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M.

Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.

21.

Nanomedicine strategies for hematological malignancies: what is next?

Visani G, Loscocco F, Isidori A.

Nanomedicine (Lond). 2014 Oct;9(15):2415-28. doi: 10.2217/nnm.14.128. Review.

PMID:
25413858
22.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A.

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. No abstract available.

23.

Reproducibility of liver iron concentration measured on a biopsy sample: a validation study in vivo.

Urru SA, Tandurella I, Capasso M, Usala E, Baronciani D, Giardini C, Visani G, Angelucci E.

Am J Hematol. 2015 Feb;90(2):87-90. doi: 10.1002/ajh.23878. Epub 2014 Nov 19.

24.

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.

Isidori A, Salvestrini V, Ciciarello M, Loscocco F, Visani G, Parisi S, Lecciso M, Ocadlikova D, Rossi L, Gabucci E, Clissa C, Curti A.

Expert Rev Hematol. 2014 Dec;7(6):807-18. doi: 10.1586/17474086.2014.958464. Epub 2014 Sep 16. Review.

PMID:
25227702
25.

Conditioning regimens in acute myeloid leukemia.

Visani G, Malagola M, Guiducci B, Lucesole M, Loscocco F, Gabucci E, Paolini S, Piccaluga PP, Isidori A.

Expert Rev Hematol. 2014 Aug;7(4):465-79. doi: 10.1586/17474086.2014.939066. Review.

PMID:
25025371
26.

Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.

Visani G, Ferrara F, Di Raimondo F, Loscocco F, Sparaventi G, Paolini S, Fuligni F, Gazzola A, Rossi M, Laginestra MA, Caraci MR, Riccardi C, Rocchi M, Visani A, Pileri SA, Piccaluga PP, Isidori A.

Leukemia. 2014 Apr;28(4):967-70. doi: 10.1038/leu.2014.31. Epub 2014 Jan 20. No abstract available.

PMID:
24441289
27.

Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.

Visani G, Guiducci B, Giardini C, Loscocco F, Ricciardi T, Isidori A.

Bone Marrow Transplant. 2014 Apr;49(4):585-7. doi: 10.1038/bmt.2013.213. Epub 2014 Jan 13. No abstract available.

PMID:
24419518
28.

Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.

Isidori A, Venditti A, Maurillo L, Buccisano F, Loscocco F, Manduzio P, Sparaventi G, Amadori S, Visani G.

Expert Rev Hematol. 2013 Dec;6(6):767-84. doi: 10.1586/17474086.2013.858018. Review.

PMID:
24219553
29.

Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?

Visani G, Isidori A.

Expert Opin Pharmacother. 2014 Jan;15(1):1-3. doi: 10.1517/14656566.2014.850491. Epub 2013 Oct 23.

PMID:
24152096
30.

High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.

Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T, Picardi P, Visani G.

Expert Rev Hematol. 2013 Aug;6(4):451-64. doi: 10.1586/17474086.2013.814451. Review.

PMID:
23991931
31.

Third party cord blood transplant boosts autologous hematopoiesis in a case of persistent bone marrow aplasia after double transplant failure for B-thalassemia major.

Visani G, Picardi P, Guiducci B, Loscocco F, Giardini C, Lucesole M, Barulli S, Ricciardi T, Isidori A.

Mediterr J Hematol Infect Dis. 2013 Apr 15;5(1):e2013029. doi: 10.4084/MJHID.2013.029. Print 2013.

32.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

33.

Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.

Latagliata R, Isidori A, Breccia M, Carmosino I, Vozella F, Volpicelli P, Finsinger P, Barulli S, Loglisci G, Santopietro M, Federico V, Diverio D, Nanni M, Mancini M, Visani G, Alimena G.

Acta Haematol. 2013;129(2):126-34. doi: 10.1159/000343384. Epub 2012 Nov 28.

34.

Autologous stem cell transplantation for aggressive lymphomas.

Visani G, Picardi P, Tosi P, Gonella R, Loscocco F, Ricciardi T, Malerba L, Guiducci B, Tomassetti S, Barulli S, Isidori A.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012075. doi: 10.4084/MJHID.2012.075. Epub 2012 Nov 7.

35.

Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma.

Tosi P, Imola M, Mianulli AM, Tomassetti S, Merli A, Molinari A, Mangianti S, Ratta M, Isidori A, Visani G.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012069. doi: 10.4084/MJHID.2012.069. Epub 2012 Nov 5.

36.

Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.

Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32. doi: 10.1016/j.clml.2012.06.008. Epub 2012 Sep 14.

PMID:
22981966
37.

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G.

Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Erratum in: Hematol Oncol. 2013 Spe;31(3):169.

PMID:
22815278
38.

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.

Russo Rossi A, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, Fava C, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G.

Haematologica. 2013 Mar;98(3):399-403. doi: 10.3324/haematol.2012.064337. Epub 2012 Jul 16.

39.

Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.

Olivieri A, Gini G, Bocci C, Montanari M, Trappolini S, Olivieri J, Brunori M, Catarini M, Guiducci B, Isidori A, Alesiani F, Giuliodori L, Marcellini M, Visani G, Poloni A, Leoni P.

Oncologist. 2012;17(5):663-72. doi: 10.1634/theoncologist.2011-0355. Epub 2012 Apr 24.

40.

SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis.

Visani G, Sapienza MR, Isidori A, Tripodo C, Laginestra MA, Righi S, Sagramoso Sacchetti CA, Gazzola A, Mannu C, Rossi M, De Nictolis M, Valentini M, Donati M, Emiliani R, Alesiani F, Paolini S, Finelli C, Pileri SA, Piccaluga PP.

PLoS One. 2011;6(11):e27560. doi: 10.1371/journal.pone.0027560. Epub 2011 Nov 14.

41.

Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm.

Littera R, Orrù N, Caocci G, Sanna M, Mulargia M, Piras E, Vacca A, Giardini C, Orofino MG, Visani G, Bertaina A, Giorgiani G, Locatelli F, Carcassi C, La Nasa G.

Br J Haematol. 2012 Jan;156(1):118-28. doi: 10.1111/j.1365-2141.2011.08923.x. Epub 2011 Nov 14.

PMID:
22077388
42.

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A.

Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.

43.

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.

Malagola M, Skert C, Vignetti M, Piciocchi A, Martinelli G, Alimena G, Mecucci C, Testoni N, Iacobucci I, Clavio M, Gobbi M, Candoni A, Damiani D, Bocchia M, Lauria F, Zaccaria A, Mazza P, Visani G, Peli A, Colombi C, Cancelli V, Mancini M, Foà R, Martelli M, Cantore N, Di Raimondo F, Petrini M, De Fabritiis P, Fioritoni G, Nobile F, Fabbiano F, Specchia G, Baccarani M, Lo Coco F, Amadori S, Mandelli F, Russo D.

Leuk Lymphoma. 2011 Dec;52(12):2329-35. doi: 10.3109/10428194.2011.596965. Epub 2011 Jul 12.

PMID:
21745171
44.

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

Visani G, Breccia M, Montefusco E, Morra E, Santini V, Isidori A.

Haematologica. 2011 Apr;96(4):e23-4; author reply e25. doi: 10.3324/haematol.2011.041319. No abstract available.

45.

Doxorubicin variants for hematological malignancies.

Visani G, Isidori A.

Nanomedicine (Lond). 2011 Feb;6(2):303-6. doi: 10.2217/nnm.10.152. No abstract available.

46.

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L.

Br J Haematol. 2011 May;153(3):351-7. doi: 10.1111/j.1365-2141.2011.08597.x. Epub 2011 Mar 4.

PMID:
21371003
47.

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.

Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P.

Leuk Lymphoma. 2011 May;52(5):776-85. doi: 10.3109/10428194.2011.555027. Epub 2011 Feb 21.

PMID:
21338282
48.

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.

Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori).

Ann Oncol. 2011 Jul;22(7):1628-35. doi: 10.1093/annonc/mdq646. Epub 2011 Jan 20.

PMID:
21252060
49.

Myeloid Sarcoma: The Clinician's Point of View.

Malagola M, Tiribelli M, Russo D, Candoni A, Visani G, Isidori A.

Leuk Res Treatment. 2011;2011:410291. doi: 10.4061/2011/410291. Epub 2011 Apr 27.

50.

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.

Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, Sabattini E, Visani G, Pileri SA.

Leuk Lymphoma. 2011 Feb;52(2):325-7. doi: 10.3109/10428194.2010.529206. Epub 2010 Nov 15. No abstract available.

PMID:
21077738

Supplemental Content

Loading ...
Support Center